STOCK TITAN

WuXi AppTec Receives 2021 Global Customer Value Leadership Award from Frost & Sullivan

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

WuXi AppTec, a global provider of R&D and manufacturing services, has received the 2021 Global CRDMO Customer Value Leadership Award from Frost & Sullivan. This marks the fifth consecutive year of recognition for WuXi AppTec's leadership in innovative services. The award acknowledges the company's exceptional customer value, enabling healthcare innovation through its unique CRDMO and CTDMO business models. These models provide end-to-end services for drug R&D and manufacturing, aiding partners in delivering new treatments efficiently.

Positive
  • Received the 2021 Global CRDMO Customer Value Leadership Award from Frost & Sullivan.
  • Recognized for five consecutive years for leadership and innovative services.
  • Unique CRDMO and CTDMO business models enhance efficiency in drug R&D and manufacturing.
Negative
  • None.

SHANGHAI, Dec. 8, 2021 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, announced that it is a recipient of the 2021 Global CRDMO Customer Value Leadership Award from Frost & Sullivan, a global research & consulting firm that helps clients accelerate growth. This marks the fifth consecutive year that WuXi AppTec has been recognized by Frost & Sullivan for its leadership and innovative services.

The Frost & Sullivan Best Practices Awards recognize companies at the forefront of their industries that consistently demonstrate leadership in innovative solutions that meet ever-evolving customer needs and are superior in overall price, performance, and quality. WuXi AppTec was honored with this award for providing unmatched customer value by enabling healthcare innovation through cost-effective and efficient solutions. WuXi AppTec's unique CRDMO (Contract Research, Development and Manufacturing Organization) and CTDMO (Contract Testing, Development and Manufacturing Organization) business models offer end-to-end services for drug R&D and manufacturing, enabling its partners to advance discoveries and deliver groundbreaking treatments to patients more quickly.

"WuXi AppTec's one-of-a-kind business model stands out in the global healthcare industry," commented Ojaswi Rana, a research analyst at Frost & Sullivan. "With customer-centricity as a fundamental value proposition, WuXi AppTec is delivering high-quality services that lower the barriers to R&D and help advance innovation across different stages of the drug development process."

"We are honored to receive this award from Frost & Sullivan, and thank them for recognizing the value of our global platform to customers," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "Through our unique CRDMO and CTDMO business models, WuXi AppTec will continue to enhance our enabling platform and serve as a trusted partner to global customers who are driving healthcare advancements and delivering innovative new drugs to patients in need."

About WuXi AppTec

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2021 and its open-access platform is enabling more than 5,600 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated." Please visit: http://www.wuxiapptec.com

Cision View original content:https://www.prnewswire.com/news-releases/wuxi-apptec-receives-2021-global-customer-value-leadership-award-from-frost--sullivan-301439902.html

SOURCE WuXi AppTec

FAQ

What award did WuXi AppTec receive in 2021?

WuXi AppTec received the 2021 Global CRDMO Customer Value Leadership Award from Frost & Sullivan.

How many years has WuXi AppTec been recognized for its leadership?

WuXi AppTec has been recognized for its leadership for five consecutive years.

What business models does WuXi AppTec offer?

WuXi AppTec offers unique CRDMO (Contract Research, Development and Manufacturing Organization) and CTDMO (Contract Testing, Development and Manufacturing Organization) business models.

What is the significance of the Frost & Sullivan award for WuXi AppTec?

The Frost & Sullivan award recognizes WuXi AppTec's exceptional customer value and innovative services in the pharmaceutical and healthcare industry.

How does WuXi AppTec contribute to healthcare innovation?

WuXi AppTec contributes to healthcare innovation by providing end-to-end services that enable rapid drug R&D and manufacturing.

WUXI APPTEC CO UNSP/ADR

OTC:WUXAY

WUXAY Rankings

WUXAY Latest News

WUXAY Stock Data

22.57B
2.42B
Diagnostics & Research
Healthcare
Link
United States of America
Shanghai